Insulin Delivery Device - Company Evaluation Report, 2025

The Insulin Delivery Devices Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Insulin Delivery Devices. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. The analyst's '360 Quadrants' evaluated over 240 companies, of which the Top 25 Insulin Delivery Devices Companies were categorized and recognized as quadrant leaders.

Insulin delivery devices such as pens, pen needles, syringes, and pumps are essential tools for diabetes patients to control their blood glucose levels. This dominance is attributed to the increasing preference for insulin pens among diabetic patients due to their ease of use, improved convenience, reduced pain during administration, enhanced dosage accuracy, and improved medication adherence.

The growth of the insulin delivery devices market is primarily driven by the rising prevalence of diabetes, ongoing technological advancements in insulin delivery solutions, and supportive government initiatives coupled with favourable reimbursement policies. These factors collectively contribute to the increasing adoption of insulin delivery devices worldwide.

The 360 Quadrant maps the Insulin Delivery Devices companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Insulin Delivery Devices quadrant. The top criteria for product footprint evaluation included By Type (Insulin Pens, Insulin Pumps, Insulin Pen Needles, Insulin Syringes, Other Insulin Delivery Devices), By Disease Type (Type 2 Diabetes, Type 1 Diabetes), and By End User (Home Care Settings, Hospitals & Clinics, Other End Users).

Key Players

Key players in the Insulin Delivery Devices market include major global corporations and specialized innovators such as Embecta Corp. (US), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Ypsomed (Switzerland), Eli Lilly and Company (US), Tandem Diabetes Care, Inc. (US), Roche Diabetes Care (Switzerland), HTL-STREFA, a subsidiary of MTD Group (Poland), Terumo Corporation (Japan), Eoflow Co., Ltd (South Korea), B.

Braun SE (Germany), Haselmeier, a subsidiary of Medmix (Germany), Insulet Corporation (US), Biocon (India), Nipro (Japan), Sooil Developments Co., Ltd (South Korea), Wockhardt (India), MannKind Corporation (US), Medtrum Technologies Inc. (China), CeQur Corporation (Switzerland), Hindustan Syringes & Medical Devices Ltd (India), Sungshim Medical Co., Ltd (South Korea), Debiotech SA (Switzerland), and Jiangsu Delfu Medical Co., Ltd (China). These companies are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation, expand their global footprint, and maintain a competitive edge in this rapidly evolving market.

Top 3 Companies

Embecta Corp.

Embecta Corp. was established on April 1, 2022, as a spin-off from Becton, Dickinson and Company (BD), inheriting BD’s legacy in diabetes care. As a global leader in medical devices, Embecta focuses exclusively on delivering diabetes care solutions aimed at improving patient health and quality of life. Its product portfolio includes a comprehensive range of pen needles, syringes, and safety injection devices. Embecta supports its global operations through a robust manufacturing, commercial, and distribution infrastructure.

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company renowned for its leadership in diabetes care. The company operates through two main business segments: Diabetes and Obesity Care and Rare Disease (formerly known as Biopharm). The company also provides innovative digital tools for diabetes management, including smart insulin pens and Dose Check, a digital application for insulin dose guidance. It maintains a robust global presence, with offices in 80 countries and product distribution spanning over 170 markets, reinforcing its commitment to improving the lives of people living with diabetes and related conditions worldwide.

Ypsomed

Ypsomed is a leading developer and manufacturer of injection and infusion systems for self-medication, with more than 40 years of experience and recognized expertise in diabetes care. The company is an independent industry leader in the production of injection pens for pharmaceutical and biotechnology companies, as well as diabetes-focused products such as insulin pumps, pen needles, and blood glucose monitoring systems.

1 Introduction

1.1 Market Definition
1.2 Inclusion and Exclusions
1.3 Stakeholders

2 Executive Summary

3 Market Overview

3.1 Introduction
3.2 Market Dynamics
3.2.1 Drivers
3.2.1.1 Growth in Prevalence of Diabetic Population
3.2.1.2 Technological Advancements in Insulin Delivery Devices
3.2.1.3 Government Support and Favorable Reimbursement Schemes to Favor the Market Growth
3.2.2 Restraints
3.2.2.1 High Cost and Lack of Reimbursement in Emerging Economies
3.2.2.2 Needle Anxiety in Patients to Affect Growth of Pen Needles and Syringes Market
3.2.2.3 Oral Insulin as Alternative Drug Delivery Method
3.2.3 Opportunities
3.2.3.1 Increase in Research & Development Activities and Strategic Partnerships
3.2.3.2 Increase in Healthcare Expenditure on Diabetes Care
3.2.3.3 Advances in Insulin Syringe and Needle Technology
3.2.3.4 Mandates Pertaining to Safety-Engineered Medical Needles
3.2.4 Challenges
3.2.4.1 Needlestick Injuries and Misuse of Injection Pens
3.2.4.2 Lack of Interoperability Among Insulin Delivery Devices
3.3 Industry Trends
3.3.1 Growing Demand for Hybrid Closed-Loop Systems/Artificial Pancreas Device Systems
3.3.2 Synchronization of Smart Insulin Pens with Continuous Glucose Monitoring Systems Promotes Diabetes Data Sharing
3.3.3 Increase in Number of Collaborations Among Stakeholders
3.4 Technology Analysis
3.4.1 Key Technologies
3.4.1.1 Automated Insulin Delivery
3.4.2 Complementary Technologies
3.4.2.1 Bluetooth
3.4.3 Adjacent Technologies
3.4.3.1 Continuous Glucose Monitoring
3.5 Key Conferences & Events
3.6 Patent Analysis
3.6.1 Patent Publication Trends for Insulin Delivery Devices
3.6.2 Jurisdiction Analysis: Top Applicants for Patents in Insulin Delivery Devices Market
3.7 Ecosystem Market Map
3.8 Porter's Five Forces Analysis
3.8.1 Intensity of Competitive Rivalry
3.8.2 Bargaining Power of Suppliers
3.8.3 Bargaining Power of Buyers
3.8.4 Threat of Substitutes
3.8.5 Threat of New Entrants
3.9 Trends/Disruption Impacting Customer's Business
3.10 Impact of AI/Generative AI on Insulin Delivery Devices Market

4 Competitive Landscape

4.1 Introduction
4.2 Key Player Strategies/Right to Win
4.2.1 Overview of Strategies Adopted by Key Players in Insulin Delivery Devices Market
4.3 Revenue Analysis, 2022-2024
4.4 Market Share Analysis, 2024
4.5 Company Evaluation Matrix: Key Players, 2024
4.5.1 Stars
4.5.2 Emerging Leaders
4.5.3 Pervasive Players
4.5.4 Participants
4.5.5 Company Footprint: Key Players, 2024
4.5.5.1 Company Footprint
4.5.5.2 Type Footprint
4.5.5.3 Region Footprint
4.6 Company Evaluation Matrix: Startups/SMEs, 2024
4.6.1 Progressive Companies
4.6.2 Responsive Companies
4.6.3 Dynamic Companies
4.6.4 Starting Blocks
4.6.5 Competitive Benchmarking
4.6.5.1 Detailed List of Key Startups/SMEs, 2024
4.6.5.2 Competitive Benchmarking of Key Startups/SMEs
4.7 Brand/Product Comparison
4.8 Company Valuation & Financial Metrics
4.8.1 Financial Metrics
4.8.2 Company Valuation
4.9 R&D Assessment of Key Players
4.10 Competitive Scenario
4.10.1 Product Launches & Approvals
4.10.2 Deals
4.10.3 Expansions
4.10.4 Other Developments

5 Company Profiles

5.1 Key Players
5.1.1 Embecta Corp. (Formerly Becton, Dickinson and Company Diabetes Care Business)
5.1.1.1 Business Overview
5.1.1.2 Products Offered
5.1.1.3 Recent Developments
5.1.1.3.1 Product Launches and Approvals
5.1.1.3.2 Deals
5.1.1.3.3 Expansions
5.1.1.3.4 Other Developments
5.1.1.4 Analyst's View
5.1.1.4.1 Right to Win
5.1.1.4.2 Strategic Choices
5.1.1.4.3 Weaknesses & Competitive Threats
5.1.2 Novo Nordisk A/S
5.1.2.1 Business Overview
5.1.2.2 Products Offered
5.1.2.3 Recent Developments
5.1.2.3.1 Product Launches and Approvals
5.1.2.3.2 Deals
5.1.2.3.3 Other Developments
5.1.2.4 Analyst's View
5.1.2.4.1 Right to Win
5.1.2.4.2 Strategic Choices
5.1.2.4.3 Weaknesses & Competitive Threats
5.1.3 Medtronic
5.1.3.1 Business Overview
5.1.3.2 Products Offered
5.1.3.3 Recent Developments
5.1.3.3.1 Product Launches and Approvals
5.1.3.3.2 Deals
5.1.3.3.3 Expansions
5.1.3.3.4 Other Developments
5.1.3.4 Analyst's View
5.1.3.4.1 Right to Win
5.1.3.4.2 Strategic Choices
5.1.3.4.3 Weaknesses & Competitive Threats
5.1.4 Sanofi
5.1.4.1 Business Overview
5.1.4.2 Products Offered
5.1.4.3 Recent Developments
5.1.4.3.1 Product Launches and Approvals
5.1.4.3.2 Expansions
5.1.4.3.3 Other Developments
5.1.4.4 Analyst's View
5.1.4.4.1 Right to Win
5.1.4.4.2 Strategic Choices
5.1.4.4.3 Weaknesses & Competitive Threats
5.1.5 Eli Lilly and Company
5.1.5.1 Business Overview
5.1.5.2 Products Offered
5.1.5.3 Recent Developments
5.1.5.3.1 Product Launches and Approvals
5.1.5.3.2 Deals
5.1.5.3.3 Expansions
5.1.5.3.4 Other Developments
5.1.5.4 Analyst's View
5.1.5.4.1 Right to Win
5.1.5.4.2 Strategic Choices
5.1.5.4.3 Weaknesses and Competitive Threats
5.1.6 Tandem Diabetes Care, Inc.
5.1.6.1 Business Overview
5.1.6.2 Products Offered
5.1.6.3 Recent Developments
5.1.6.3.1 Product Launches and Approvals
5.1.6.3.2 Deals
5.1.7 Insulet Corporation
5.1.7.1 Business Overview
5.1.7.2 Products Offered
5.1.7.3 Recent Developments
5.1.7.3.1 Product Launches and Approvals
5.1.7.3.2 Deals
5.1.7.3.3 Expansions
5.1.7.3.4 Other Developments
5.1.8 Biocon
5.1.8.1 Business Overview
5.1.8.2 Products Offered
5.1.8.3 Recent Developments
5.1.8.3.1 Deals
5.1.8.3.2 Other Developments
5.1.9 Roche Diabetes Care
5.1.9.1 Business Overview
5.1.9.2 Products Offered
5.1.9.3 Recent Developments
5.1.9.3.1 Product Launches and Approvals
5.1.10 Htl-Strefa (Subsidiary of the Mtd Group)
5.1.10.1 Business Overview
5.1.10.2 Products Offered
5.1.10.3 Recent Developments
5.1.10.3.1 Deals
5.1.11 Ypsomed
5.1.11.1 Business Overview
5.1.11.2 Products Offered
5.1.11.3 Recent Developments
5.1.11.3.1 Product Launches and Approvals
5.1.11.3.2 Deals
5.1.11.3.3 Expansions
5.1.11.3.4 Other Developments
5.1.12 Medtrum Technologies Inc.
5.1.12.1 Business Overview
5.1.12.2 Products Offered
5.1.13 Terumo Corporation
5.1.13.1 Business Overview
5.1.13.2 Products Offered
5.1.13.3 Recent Developments
5.1.13.3.1 Product Launches and Approvals
5.1.13.3.2 Deals
5.1.13.3.3 Expansions
5.1.13.3.4 Other Developments
5.1.14 Wockhardt Limited
5.1.14.1 Business Overview
5.1.14.2 Products Offered
5.1.14.3 Recent Developments
5.1.14.3.1 Product Launches and Approvals
5.1.14.3.2 Other Developments
5.1.15 Nipro
5.1.15.1 Business Overview
5.1.15.2 Products Offered
5.1.15.3 Recent Developments
5.1.15.3.1 Expansions
5.2 Other Players
5.2.1 Cequr Corporation
5.2.2 Eoflow Co. Ltd.
5.2.3 Hindustan Syringes & Medical Devices Ltd.
5.2.4 Sooil Developments Co. Ltd.
5.2.5 Sungshim Medical Co. Ltd.
5.2.6 B.Braun SE
5.2.7 Debiotech SA
5.2.8 Jiangsu Delfu Medical Device Co. Ltd.
5.2.9 Haselmeier (A Subsidiary of Medmix)
5.2.10 Mannkind Corporation

6 Appendix

6.1 Research Methodology
6.1.1 Research Data
6.1.1.1 Secondary Data
6.1.1.2 Primary Data
6.1.2 Assumptions for Study
6.1.3 Research Limitations
6.1.4 Risk Assessment
6.2 Company Evaluation Matrix: Methodology

List of Tables

Table 1 Top 10 Countries/Territories with Highest Number of Adults (20-79 Years) with Diabetes, 2024 and 2050 (Million)
Table 2 Total Diabetes-Related Health Expenditure Across Regions, 2024 and 2050 (USD Million)
Table 3 Hybrid Closed-Loop Systems: Current Market Scenario
Table 4 Major Smart Insulin Pens Available Globally
Table 5 Recent Collaborations in Insulin Delivery Device Market
Table 6 Insulin Delivery Devices Market: Detailed List of Conferences & Events, 2025-2026
Table 7 List of Patents in Insulin Delivery Devices Market, 2022-2024
Table 8 Insulin Delivery Devices Market: Porter's Five Forces Analysis
Table 9 Overview of Strategies Deployed by Key Players in Insulin Delivery Devices Market
Table 10 Insulin Delivery Device Market: Degree of Competition
Table 11 Insulin Delivery Devices Market: Type Footprint, 2024
Table 12 Insulin Delivery Devices Market: Region Footprint, 2024
Table 13 Insulin Delivery Devices Market: Detailed List of Key Startups/SMEs, 2024
Table 14 Insulin Delivery Devices Market: Competitive Benchmarking of Key Startups/SMEs, 2024
Table 15 Insulin Delivery Devices Market: Product Launches & Approvals, January 2022-April 2025
Table 16 Insulin Delivery Devices Market: Deals, January 2022-April 2025
Table 17 Insulin Delivery Devices Market: Expansions, January 2022-April 2025
Table 18 Insulin Delivery Devices Market: Other Developments, January 2022-April 2025
Table 19 Embecta Corp.: Business Overview
Table 20 Embecta Corp.: Products Offered
Table 21 Embecta Corp: Products Launches & Approvals
Table 22 Embecta Corp: Deals
Table 23 Embecta Corp: Expansions
Table 24 Embecta Corp.: Other Developments
Table 25 Novo Nordisk A/S: Business Overview
Table 26 Novo Nordisk A/S: Products Offered
Table 27 Novo Nordisk A/S: Products Launches & Approvals
Table 28 Novo Nordisk A/S: Deals
Table 29 Novo Nordisk A/S: Other Developments
Table 30 Medtronic: Business Overview
Table 31 Medtronic: Products Offered
Table 32 Medtronic: Product Launches & Approvals
Table 33 Medtronic: Deals
Table 34 Medtronic: Expansions
Table 35 Medtronic: Other Developments
Table 36 Sanofi: Business Overview
Table 37 Sanofi: Products Offered
Table 38 Sanofi: Product Launches & Approvals
Table 39 Sanofi: Expansions
Table 40 Sanofi: Other Developments
Table 41 Eli Lilly and Company: Business Overview
Table 42 Eli Lilly and Company: Products Offered
Table 43 Eli Lilly and Company: Products Launches
Table 44 Eli Lilly and Company: Deals
Table 45 Eli Lilly and Company: Expansions
Table 46 Eli Lilly and Company: Other Developments
Table 47 Tandem Diabetes Care, Inc.: Business Overview
Table 48 Tandem Diabetes Care, Inc.: Products Offered
Table 49 Tandem Diabetes Care, Inc.: Products Launches & Approvals
Table 50 Tandem Diabetes Care, Inc.: Deals
Table 51 Insulet Corporation: Business Overview
Table 52 Insulet Corporation: Products Launches & Approvals
Table 53 Insulet Corporation: Deals
Table 54 Insulet Corporation: Expansions
Table 55 Insulet Corporation: Other Developments
Table 56 Biocon: Business Overview
Table 57 Biocon: Products Offered
Table 58 Biocon: Deals
Table 59 Biocon: Other Developments
Table 60 F. Hoffmann-La Roche: Business Overview
Table 61 F. Hoffmann-La Roche: Products Offered
Table 62 Hoffmann-La Roche Ltd.: Products Launches
Table 63 Htl-Strefa (Subsidiary of the Mtd Group): Business Overview
Table 64 Htl-Strefa (Subsidiary of the Mtd Group): Products Offered
Table 65 Htl-Strefa (Subsidiary of the Mtd Group): Deals
Table 66 Ypsomed: Business Overview
Table 67 Ypsomed: Products Offered
Table 68 Ypsomed: Product Launches & Approvals
Table 69 Ypsomed: Deals
Table 70 Ypsomed: Expansions
Table 71 Ypsomed: Other Developments
Table 72 Medtrum Technologies Inc.: Business Overview
Table 73 Medtrum Technologies Inc.: Product Portfolio
Table 74 Terumo Corporation: Business Overview
Table 75 Terumo Corporation: Products Offered
Table 76 Terumo Corporation: Product Launches
Table 77 Terumo Corporation: Deals
Table 78 Terumo Corporation: Expansions
Table 79 Terumo Corporation: Other Developments
Table 80 Wockhardt Limited: Business Overview
Table 81 Wockhardt Limited: Products Offered
Table 82 Wockhardt Limited: Products Launches
Table 83 Wockhardt Limited: Other Developments
Table 84 Nipro: Business Overview
Table 85 Nipro: Products Offered
Table 86 Nipro: Expansions
Table 87 Risk Assessment: Insulin Delivery Devices Market

List of Figures

Figure 1 Insulin Delivery Devices Market, by Type, 2025 vs. 2030 (USD Million)
Figure 2 Insulin Delivery Devices Market, by Disease Type, 2025 vs. 2030 (USD Million)
Figure 3 Insulin Delivery Devices Market, by End-user, 2025 vs. 2030 (USD Million)
Figure 4 Geographical Snapshot of Insulin Delivery Devices Market
Figure 5 Insulin Delivery Devices Market: Drivers, Restraints, Opportunities, and Challenges
Figure 6 Estimates of Global Prevalence of Diabetes in 20-79-Year Age Group, 2011-2024 (Million)
Figure 7 Diabetes Age-Standardized Prevalence in People (65-99 Years), by Region, 2024 and 2050 (Million)
Figure 8 Advancements in Insulin Delivery Devices
Figure 9 Top Patent Applicants and Owners (Companies/Institutes) for Insulin Delivery Devices Market, January 2014-December 2024
Figure 10 Top Patent Applicant Countries for Insulin Delivery Devices, January 2014-December 2024
Figure 11 Insulin Delivery Device Market: Ecosystem Mapping
Figure 12 Insulin Delivery Devices Market: Porter's Five Forces Analysis
Figure 13 Revenue Share Analysis of Key Players, 2022-2024 (USD Million)
Figure 14 Market Share Analysis of Key Players, 2024
Figure 15 Insulin Delivery Devices Market: Company Evaluation Matrix (Key Players), 2024
Figure 16 Insulin Delivery Devices Market: Company Footprint, 2024
Figure 17 Insulin Delivery Devices Market: Company Evaluation Matrix (Startups/SMEs), 2024
Figure 18 Insulin Delivery Devices Market: Brand/Product Comparative Analysis
Figure 19 EV/EBITDA of Key Vendors, 2024
Figure 20 Year-To-Date (YTD) Price Total Return and 5-Year Stock Beta of Key Vendors, 2024
Figure 21 R&D Assessment of Key Players
Figure 22 Embecta Corp.: Company Snapshot, 2024
Figure 23 Novo Nordisk A/S: Company Snapshot, 2024
Figure 24 Medtronic: Company Snapshot, 2024
Figure 25 Sanofi: Company Snapshot, 2024
Figure 26 Eli Lilly and Company: Company Snapshot, 2024
Figure 27 Tandem Diabetes Care, Inc.: Company Snapshot, 2024
Figure 28 Insulet Corporation: Company Snapshot, 2024
Figure 29 Biocon: Company Snapshot, 2024
Figure 30 F. Hoffmann-La Roche: Company Snapshot, 2024
Figure 31 Ypsomed: Company Snapshot, 2024
Figure 32 Terumo Corporation: Company Snapshot, 2024
Figure 33 Wockhardt Limited: Company Snapshot, 2024
Figure 34 Nipro: Company Snapshot, 2024
Figure 35 Research Design

Companies Mentioned

Embecta Corp. (Formerly Becton, Dickinson and Company Diabetes Care Business)
Novo Nordisk A/S
Medtronic
Sanofi
Eli Lilly and Company
Tandem Diabetes Care, Inc.
Insulet Corporation
Biocon
Roche Diabetes Care
Htl-Strefa (Subsidiary of the Mtd Group)
Ypsomed
Medtrum Technologies Inc.
Terumo Corporation
Wockhardt Limited
Nipro
Cequr Corporation
Eoflow Co. Ltd.
Hindustan Syringes & Medical Devices Ltd.
Sooil Developments Co. Ltd.
Sungshim Medical Co. Ltd.
B.Braun SE
Debiotech SA
Jiangsu Delfu Medical Device Co. Ltd.
Haselmeier (A Subsidiary of Medmix)
Mannkind Corporation

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2359EUR$2,650USD£2,039GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€3784EUR$4,250USD£3,270GBP

Key Players

Top 3 Companies

Embecta Corp.

Novo Nordisk A/S

Ypsomed

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Insulin Delivery Device Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (Tethered, Tubeless), Insulin Pen Needle (Standard, Safety), Insulin Syringes, Others), Disease Type (Type 1 Diabetes, Type 2 Diabetes) - Global Forecast to 2030

Insulin Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

Insulin Delivery Devices Market by Delivery Method (Insulin Pens, Insulin Pumps, Insulin Syringes), Insulin Type (Intermediate-Acting, Long-Acting, Pre-Mixed), Distribution Channel, End User, Application, Age Group - Global Forecast 2025-2030

Insulin Delivery Devices Market Report 2025

Smart Insulin Pens Market Report 2025